Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.…
Vistin Pharma ASA (VISTN): Key information relating to the cash dividend
Aker BPs sjeføkonom selger unna Aker-aksjer: – Ikke lurt å ha alle eggene i en kurv
Vistin Pharma (OSL: VISTN) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 74 employees.
The shares were at 19.00 NOK on 20 November 2026, down 6.4% over 52 weeks. Its 52-week range is 17.70 NOK to 23.50 NOK: the price is 19.1% below the high and 7.3% above the low.
At a market capitalisation of 842.55M NOK, it trades at 13.1 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a discount of 47% for VISTN. It pays a dividend yielding 5.13% (it pays out 70% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Vistin Pharma reports return on equity of 22.7%, an operating margin of 16.5% and flat revenue year over year.
It holds more cash than debt, a net cash position of 22.02M NOK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. The next earnings report is expected on 11 February 2027.